Molecular methods for detection of prognostic and predictive markers in diagnosis of adenoid cystic carcinoma of the salivary gland origin

Česká verzia

Authors: Petr Šteiner ^1,2; Jaroslav Pavelka ³; Tomáš Vaneček ^1,2; Markéta Miesbauerová ^1,2; Alena Skálová ^1,2
Authors place of work: Šiklův ústav patologie, Univerzita Karlova v Praze, Lékařská fakulta v Plzni, Plzeň ¹; Bioptická laboratoř, s. r. o., Plzeň ²; Západočeská Univerzita v Plzni, Pedagogická fakulta, Plzeň ³
Published in the journal: Čes.-slov. Patol., 54, 2018, No. 3, p. 132-136
Category: Původní práce

Summary

Adenoid cystic carcinoma of salivary gland origin (AdCC) is second most common salivary carcinoma characterized by frequent recurrences, perineural invasion and high long-term mortality rate. The surgical resection of the tumor in combination with adjuvant radiotherapy is the only method of choice. AdCC has been studied, altogether with immunohistochemistry, by numerous molecular-genetic techniques. Some of them, e.g. reverse-transcription PCR or fluorescent in situ hybridization contributed to the identification of translocation t(6;9)(q22-23;p23-24), which results in fusion of two transcription factors MYB-NFIB. For AdCC is this fusion unique among salivary gland carcinomas and serves as a diagnostical tool in differential diagnosis of histopathologically difficult cases. More complex methods, such as next-generation sequencing helped to detect other molecular level changes; and hence improved understanding of a development, behavior and pathogenesis of this possibly fatal malignancy.

This review summarizes basic knowledge of AdCC on the genome, transcriptome and epigenetic level, which were achieved using molecular-genetic and immunohistochemical methods.

Keywords:

adenoid cystic carcinoma – salivary carcinoma – MYB-NFIB – FISH – aCGH – NGS

Zdroje

1. Amit M, Binenbaum Y, Trejo-Leider L, et al. International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck 2015; 37(7): 1038-1045.

2. Stenam G, Licitra L, Said-Al-Naief N, van Zante A, Yarbrough WG. Adenoid Cystic Carcinoma. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, eds. World Health Organization (WHO) Classification of Head and Neck Tumours. (4th ed). Lyon, France: IARC Press; 2017: 164-165.

3. Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol 2013; 7 Suppl 1: S12-19.

4. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009; 106(44): 18740-18744.

5. Stenman G, Persson F, Andersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol 2014; 50(8): 683-690.

6. Simpson RH, Skálová A, Di Palma S, Leivo I. Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch 2014; 465(4): 371-384.

7. West RB, Kong C, Clarke N, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 2011; 35(1): 92-99.

8. Brill LB, Kanner WA, Fehr A, et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 2011; 24(9): 1169-1176.

9. Rooney SL, Robinson RA. Immunohistochemical expression of MYB in salivary gland basal cell adenocarcinoma and basal cell adenoma. J Oral Pathol Med. In press 2017.

10. Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res 2010; 16(19): 4722-4731.

11. Freier K, Flechtenmacher C, Walch A, et al. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol 2005; 41(9): 934-939.

12. Greer RO, Said S, Shroyer KR, Marileila VG, Weed SA. Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma. Oral Oncol 2007; 43(8): 735-741.

13. Szuhai K, Vermeer M. Microarray Techniques to Analyze Copy-Number Alterations in Genomic DNA: Array Comparative Genomic Hybridization and Single-Nucleotide Polymorphism Array. J Invest Dermatol 2015; 135(10): e37.doi:10.1038/jid.2015.308

14. Bernheim A, Toujani S, Saulnier P, et al. High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab Invest 2008; 88(5): 464-473.

15. Ylstra B, van den Ijssel P, Carvalho B, Brakenhoff RH, Meijer GA. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res 2006; 34(2): 445-450.

16. Ohtomo R, Mori T, Shibata S, et al. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol 2013; 26(8): 1041-1050.

17. Ivanov SV, Panaccione A, Nonaka D, et al. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. Br J Cancer 2013; 109(2): 444-451.

18. Chen W, Zhang HL, Shao XJ, et al. Gene expression profile of salivary adenoid cystic carcinoma associated with perineural invasion. Tohoku J Exp Med 2007; 212(3): 319-334.

19. Ambardar S, Gupta R, Trakroo D, Lal R, Vakhlu J. High Throughput Sequencing: An Overview of Sequencing Chemistry. Indian J Microbiol 2016; 56(4): 394-404.

20. Apaga DL, Dennis SE, Salvador JM, Calacal GC, De Ungria MC. Comparison of Two Massively Parallel Sequencing Platforms using 83 Single Nucleotide Polymorphisms for Human Identification. Sci Rep 2017; 7(1): 398.

21. Mitani Y, Liu B, Rao PH, et al. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res 2016; 22(3): 725-733.

22. Brayer KJ, Frerich CA, Kang H, Ness SA. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. Cancer Discov 2016; 6(2): 176-187.

23. Stephens PJ, Davies HR, Mitani Y, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 2013; 123(7): 2965-2968.

24. Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013; 45(7): 791-798.

25. Bell D, Bell AH, Bondaruk J, Hanna EY, Weber RS. In-depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type. Cancer 2016; 122(10): 1513-1522.

26. Maruya S, Kurotaki H, Wada R, Saku T, Shinkawa H, Yagihashi S. Promoter methylation and protein expression of the E-cadherin gene in the clinicopathologic assessment of adenoid cystic carcinoma. Mod Pathol 2004; 17(6): 637-645.

27. Zhang CY, Mao L, Li L, et al. Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer 2007; 110(1): 87-95.

28. Guo XL, Sun SZ, Wei FC. [Mechanisms of p16 gene inactivation salivary adenoid cystic carcinoma]. Hua Xi Kou Qiang Yi Xue Za Zhi 2005; 23(5): 418-420.

29. Li J, El-Naggar A, Mao L. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 2005; 104(4): 771-776.

30. Williams MD, Chakravarti N, Kies MS, et al. Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 2006; 12(24): 7353-7358.

31. Sasahira T, Kurihara M, Yamamoto K, Bhawal UK, Kirita T, Kuniyasu H. Downregulation of runt-related transcription factor 3 associated with poor prognosis of adenoid cystic and mucoepidermoid carcinomas of the salivary gland. Cancer Sci 2011; 102(2): 492-497.

32. Shao C, Bai W, Junn JC, et al. Evaluation of MYB promoter methylation in salivary adenoid cystic carcinoma. Oral Oncol 2011; 47(4): 251-255.

33. Tan M, Shao C, Bishop JA, et al. Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. Otolaryngol Head Neck Surg 2014; 150(5): 801-807.

34. Bell A, Bell D, Weber RS, El-Naggar AK. CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer 2011; 117(13): 2898-2909.

35. Bell D, Bell A, Roberts D, Weber RS, El-Naggar AK. Developmental transcription factor EN1--a novel biomarker in human salivary gland adenoid cystic carcinoma. Cancer 2012; 118(5): 1288-1292.

36. Nordkvist A, Mark J, Gustafsson H, Bang G, Stenman G. Non-random chromosome rearrangements in adenoid cystic carcinoma of the salivary glands. Genes Chromosomes Cancer 1994; 10(2): 115-121.

37. Mitani Y, Rao PH, Futreal PA, et al. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res 2011; 17(22): 7003-7014.

38. Hudson JB, Collins BT. MYB gene abnormalities t(6;9) in adenoid cystic carcinoma fine-needle aspiration biopsy using fluorescence in situ hybridization. Arch Pathol Lab Med 2014; 138(3): 403-409.

39. Rettig EM, Tan M, Ling S, et al. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. Laryngoscope 2015; 125(9): E292-299.

40. Tian Z, Li L, Zhang CY, Gu T, Li J. Differences in MYB expression and gene abnormalities further confirm that salivary cribriform basal cell tumors and adenoid cystic carcinoma are two distinct tumor entities. J Oral Pathol Med 2016; 45(9): 698-703.

41. Argyris PP, Wetzel SL, Greipp P, et al. Clinical utility of myb rearrangement detection and p63/p40 immunophenotyping in the diagnosis of adenoid cystic carcinoma of minor salivary glands: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 121(3): 282-289.

42. Hauer L, Skálová A, Šteiner P, et al. Adenoidně cystický karcinom slinných žláz. Soubor 27 pacientů. Česká Stomatologie 2016; 116(3): 57-65.

43. Rao PH, Roberts D, Zhao YJ, et al. Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res 2008; 14(16): 5181-5187.

44. Oga A, Uchida K, Nakao M, et al. Loss of 6q or 8p23 is associated with the total number of DNA copy number aberrations in adenoid cystic carcinoma. Oncol Rep 2011; 26(6): 1393-1398.

45. Freier K, Flechtenmacher C, Walch A, et al. Copy number gains on 22q13 in adenoid cystic carcinoma of the salivary gland revealed by comparative genomic hybridization and tissue microarray analysis. Cancer Genet Cytogenet 2005; 159(1): 89-95.